Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Validating a novel microfluidic platform as an ex vivo tumour model for sarcoma drug discovery
FY 2022-23
Summary
Sarcomas are a rare group of mesenchymal cancers that routinely spread to other parts of the body. In these cases, the median survival rate of patients is very poor due to a low response rate to traditional systemic therapies. More recently, immunotherapy has emerged as a potential next step in the treatment of sarcoma following recent characterizations of its immune microenvironment. However, current preclinical models for sarcoma drug discovery cannot fully replicate the microenvironment of human tumours, limiting their ability to correctly predict clinical outcomes in patients. Cell cultures fail to mimic the tridimensionality of solid tumours, and mouse models are limited due to inherent biological differences between mice and humans. A potential solution to this problem is a tumour-on-chip platform that uses microfluidics to culture sub-millimeter micro-dissections of patient tumours (MDTs). This device can house up to 32 MDTs in four separate channels, allowing for high-throughput parallel testing of different treatment conditions within the same device. My proposed project involves validating this platform for use in sarcoma research. This will include an assessment of MDT viability and genetic composition within the device over time. Additionally, an immune profile of the MDTs will be defined using immunohistochemistry and RNA sequencing. The relative abundance of key immune cells will then be compared to the source tumour to examine whether the MDTs are a representative model of the patient tumour. If so, the MDT-on-chip platform could greatly benefit sarcoma research by providing a versatile tool for patient-specific drug-testing in both the lab and the clinic.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486298
Name
Kamal Kousha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validating a novel microfluidic platform as an ex vivo tumour model for sarcoma drug discovery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Drug Discovery; Immunotherapy; Lab-On-Chip; Microfluidics; Sarcoma
Abstract
Sarcomas are a rare group of mesenchymal cancers that routinely spread to other parts of the body. In these cases, the median survival rate of patients is very poor due to a low response rate to traditional systemic therapies. More recently, immunotherapy has emerged as a potential next step in the treatment of sarcoma following recent characterizations of its immune microenvironment. However, current preclinical models for sarcoma drug discovery cannot fully replicate the microenvironment of human tumours, limiting their ability to correctly predict clinical outcomes in patients. Cell cultures fail to mimic the tridimensionality of solid tumours, and mouse models are limited due to inherent biological differences between mice and humans. A potential solution to this problem is a tumour-on-chip platform that uses microfluidics to culture sub-millimeter micro-dissections of patient tumours (MDTs). This device can house up to 32 MDTs in four separate channels, allowing for high-throughput parallel testing of different treatment conditions within the same device. My proposed project involves validating this platform for use in sarcoma research. This will include an assessment of MDT viability and genetic composition within the device over time. Additionally, an immune profile of the MDTs will be defined using immunohistochemistry and RNA sequencing. The relative abundance of key immune cells will then be compared to the source tumour to examine whether the MDTs are a representative model of the patient tumour. If so, the MDT-on-chip platform could greatly benefit sarcoma research by providing a versatile tool for patient-specific drug-testing in both the lab and the clinic.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kamal, Kousha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~